Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan-Mar;14(1):7-16.
doi: 10.25122/jml-2020-0145.

The epidemiology of myasthenia gravis

Affiliations
Review

The epidemiology of myasthenia gravis

Ana-Maria Bubuioc et al. J Med Life. 2021 Jan-Mar.

Abstract

Neuromuscular junction (NMJ) disorders include several dysfunctions that ultimately lead to muscle weakness. Myasthenia gravis (MG) is the most prevalent NMJ disorder with a highly polymorphic clinical presentation and many different faces. Being an autoimmune disease, MG correlates with the presence of detectable antibodies directed against the acetylcholine receptor, muscle-specific kinase, lipoprotein-related protein 4, agrin, titin, and ryanodine in the postsynaptic membrane at the NMJ. MG has become a prototype serving to understand both autoimmunity and the function of the NMJ better. The aim of this review is to synthesize some of the epidemiological data available. Epidemiological data regarding MG are important for postulating hypotheses regarding its etiology and facilitating the description of MG subtypes. Thus, adequate documentation through broad databases is essential. The incidence and prevalence of MG reported around the globe have been rising steadily and consistently over the past decades. Ethnic aspects, gender-related differences, and environmental risk factors have been described, implying that these might contribute to a specific phenotype, further suggesting that MG may be considered an umbrella term that covers several clinical entities.

Keywords: autoimmunity; epidemiology; incidence; myasthenia gravis; prevalence.

PubMed Disclaimer

References

    1. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010:10. - PMC - PubMed
    1. Gilhus NE. Autoimmune myasthenia gravis. 2009;9(3):351–8. - PubMed
    1. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle and Nerve. 2004;29(4):484–505. - PubMed
    1. Gilhus NE, Verschuuren JJ. Myasthenia gravis : subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023–36. - PubMed
    1. Phillips LH. The epidemiology of myasthenia gravis. Semin Neurol. 2004;24(1):17–20. - PubMed